Diagnostic value of β-D-glucan alone or combined with Candida score, colonization index and C-reactive protein for candidemia
Copyright (c) 2022 Sumeyye Kazancioglu, Aliye Bastug, Bircan Kayaaslan, Nevzat Mehmet Mutlu, Esin Calci, Turan Turhan, Ipek Mumcuoglu, Esragul Akinci, Hurrem Bodur..
INTRODUCTION: Candidemia causes high mortality and is occuring at increasing rate in intensive care units (ICUs). (1,3)- β-D-glucan (BDG) testing is recommended in neutropenic patients. However the usefulness of BDG in ICUs is unclear.
METHODOLOGY: This study was conducted to compare the diagnostic value of Candida score (CS), colonization index (CI), serum BDG detection, and routine laboratory parameters in ICU patients. Characteristics and laboratory data of 83 patients (15 patients with candidemia and 68 patients without candidemia) were evaluated.
RESULTS: Median serum BDG was significantly higher in the candidemia group (129 pg/mL vs. 36 pg/mL, p < 0.001). BDG assay with standard cut-off value ≥ of 80 pg/mL had 93.33% sensitivity and 64.18% specificity (Areas under the ROC curve (AUC): 0.788). This study concluded that the optimal cut-off value for BDG assay was 112 pg/mL with sensitivity of 86.67% and specificity of 82.09% (AUC: 0.844). C-reactive protein (CRP) with optimal cut-off value ≥ 85 mg/L and BDG ≥ 80 pg/mL had the highest AUC (0.862, 95% CI: 0.768 - 0.928) with sensitivity 93.33% and specificity 79.1%.
CONCLUSIONS: Predicting candidemia is essential in critically ill patients who are at high risk and have high mortality rates. The results of this study suggest that BDG testing is useful for predicting candidemia in ICU. However, BDG combined with CRP may be a stronger predictor for candidemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of infection in developing countries - 16(2022), 2 vom: 28. Feb., Seite 362-368 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kazancioglu, Sumeyye [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(1,3)-β-D-glucan |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3855/jidc.15711 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338290737 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338290737 | ||
| 003 | DE-627 | ||
| 005 | 20231226000335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3855/jidc.15711 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338290737 | ||
| 035 | |a (NLM)35298433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kazancioglu, Sumeyye |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic value of β-D-glucan alone or combined with Candida score, colonization index and C-reactive protein for candidemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2022 Sumeyye Kazancioglu, Aliye Bastug, Bircan Kayaaslan, Nevzat Mehmet Mutlu, Esin Calci, Turan Turhan, Ipek Mumcuoglu, Esragul Akinci, Hurrem Bodur. | ||
| 520 | |a INTRODUCTION: Candidemia causes high mortality and is occuring at increasing rate in intensive care units (ICUs). (1,3)- β-D-glucan (BDG) testing is recommended in neutropenic patients. However the usefulness of BDG in ICUs is unclear | ||
| 520 | |a METHODOLOGY: This study was conducted to compare the diagnostic value of Candida score (CS), colonization index (CI), serum BDG detection, and routine laboratory parameters in ICU patients. Characteristics and laboratory data of 83 patients (15 patients with candidemia and 68 patients without candidemia) were evaluated | ||
| 520 | |a RESULTS: Median serum BDG was significantly higher in the candidemia group (129 pg/mL vs. 36 pg/mL, p < 0.001). BDG assay with standard cut-off value ≥ of 80 pg/mL had 93.33% sensitivity and 64.18% specificity (Areas under the ROC curve (AUC): 0.788). This study concluded that the optimal cut-off value for BDG assay was 112 pg/mL with sensitivity of 86.67% and specificity of 82.09% (AUC: 0.844). C-reactive protein (CRP) with optimal cut-off value ≥ 85 mg/L and BDG ≥ 80 pg/mL had the highest AUC (0.862, 95% CI: 0.768 - 0.928) with sensitivity 93.33% and specificity 79.1% | ||
| 520 | |a CONCLUSIONS: Predicting candidemia is essential in critically ill patients who are at high risk and have high mortality rates. The results of this study suggest that BDG testing is useful for predicting candidemia in ICU. However, BDG combined with CRP may be a stronger predictor for candidemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (1,3)-β-D-glucan | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a Candidemia | |
| 650 | 4 | |a ICU | |
| 650 | 7 | |a Proteoglycans |2 NLM | |
| 650 | 7 | |a beta-Glucans |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Bastug, Aliye |e verfasserin |4 aut | |
| 700 | 1 | |a Kayaaslan, Bircan |e verfasserin |4 aut | |
| 700 | 1 | |a Mutlu, Nevzat Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Calci, Esin |e verfasserin |4 aut | |
| 700 | 1 | |a Turhan, Turan |e verfasserin |4 aut | |
| 700 | 1 | |a Mumcuoglu, Ipek |e verfasserin |4 aut | |
| 700 | 1 | |a Akinci, Esragul |e verfasserin |4 aut | |
| 700 | 1 | |a Bodur, Hurrem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection in developing countries |d 2007 |g 16(2022), 2 vom: 28. Feb., Seite 362-368 |w (DE-627)NLM191178497 |x 1972-2680 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:2 |g day:28 |g month:02 |g pages:362-368 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3855/jidc.15711 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 2 |b 28 |c 02 |h 362-368 | ||